Subsequently in 2010, Kochenderfer et al. at the NIH reported the first successful use of anti-CD19 CAR T-cell treatment in a patient with advanced follicular lymphoma who received cyclophosphamide and fludarabine conditioning followed by a single infusion of autologous T-cells retrovirally transduced with a 2nd generation CD19 CAR (CD28 costimulatory domain) along with IL-2[165]. The gene discussed is CD19; the disease is follicular lymphoma.